Contrasting Protalix BioTherapeutics (NYSE:PLX) and Pharming Group (NASDAQ:PHAR)

Protalix BioTherapeutics (NYSE:PLX) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Protalix BioTherapeutics has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500.

Profitability

This table compares Protalix BioTherapeutics and Pharming Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Pharming Group	6.23%	8.70%	4.93%

Valuation & Earnings

This table compares Protalix BioTherapeutics and Pharming Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$84.69 million	2.98	$8.31 million	$0.25	12.52
Pharming Group	$376.13 million	2.47	$2.85 million	$0.32	41.02

Protalix BioTherapeutics has higher earnings, but lower revenue than Pharming Group. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Protalix BioTherapeutics and Pharming Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0	0	1	0	3.00
Pharming Group	1	1	3	0	2.40

Protalix BioTherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 283.39%. Pharming Group has a consensus target price of $39.67, indicating a potential upside of 202.22%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Protalix BioTherapeutics is more favorable than Pharming Group.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins for the treatment of rare and serious diseases. The company is headquartered in Israel and uses its proprietary ProCellEx plant-cell-based protein expression platform to produce biologic medicines. Protalix’s commercial products include Elfabrio (pegunigalsidase alfa), a treatment for adults with Fabry disease, and Elelyso (taliglucerase alfa), an enzyme replacement therapy for adults with Gaucher disease.

About Pharming Group

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).